1. Double Trap Interface: A novel gas interface for high throughput analysis of biomedical samples by AMS.
- Author
-
De Maria D, Fahrni SM, Lozac'h F, Marvalin C, Walles M, Camenisch G, Wacker L, and Synal HA
- Subjects
- Carbon Radioisotopes, Gas Chromatography-Mass Spectrometry methods, High-Throughput Screening Assays instrumentation, High-Throughput Screening Assays methods, Humans, Isotope Labeling methods, Scintillation Counting methods, Pharmaceutical Preparations analysis, Pharmaceutical Preparations metabolism, Pharmacokinetics
- Abstract
Although Accelerator Mass Spectrometry (AMS) offers unparalleled sensitivity by investigating the fate of
14 C-labeled compounds within the organism, its widespread use in ADME (absorption, distribution, metabolism, excretion) studies is limited. Conventional approaches based on Liquid Scintillation Counting (LSC) are still preferred, in particular because of complexity and costs associated with AMS measurements. Progress made over the last decade towards more compact AMS systems increased the interest in a combustion-based AMS approach allowing the analysis of samples in gaseous form. Thus, a novel gas Double Trap Interface (DTI) was designed, providing high sample throughput for the analysis of biomedical samples. DTI allows the coupling of an Elemental Analyzer (EA) for sample combustion to the hybrid ion source of a MICADAS (MIni CArbon DAting System) AMS system. The performance was evaluated in two studies through the analysis of more than 1000 samples from14 C-labeled biomatrices and fractions collected after liquid chromatography (LC). The covered activity ranged from 1 to 1000 mBq/g for labeled biomatrices and from 1 to 10000 mBq/g(C) for LC fractions. The implemented routine allows automated measurements requiring less than 5 min per sample (12-13 analyses per hour) without the need for sample conversion to graphite., Competing Interests: Declaration of competing interest F Lozac'h, C Marvalin, M Walles and G Camenisch are employees of Novartis Pharma AG. S Fahrni is an employee of Ionplus AG. L Wacker, H-A Synal and S Fahrni are shareholders of Ionplus AG. There is no competing financial interest between Novartis and Ionplus on this project. D De Maria has no financial involvement with any organization or financial interest with the subject discussed in the manuscript., (Copyright © 2021 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF